TISIDB

Summary
Symbol	FANCM
Name	Fanconi anemia, complementation group M
Aliases	FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location	14q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF02732 ERCC4 domain PF16783 FANCM to MHF binding domain PF00271 Helicase conserved C-terminal domain PF04851 Type III restriction enzyme
Function	DNA-dependent ATPase component of the Fanconi anemia (FA) core complex (PubMed:16116422). Required for the normal activation of the FA pathway, leading to monoubiquitination of the FANCI-FANCD2 complex in response to DNA damage, cellular resistance to DNA cross-linking drugs, and prevention of chromosomal breakage (PubMed:16116422, PubMed:19423727, PubMed:20347428, PubMed:20347429). In complex with CENPS and CENPX, binds double-stranded DNA (dsDNA), fork-structured DNA (fsDNA) and Holliday junction substrates (PubMed:20347428, PubMed:20347429). Its ATP-dependent DNA branch migration activity can process branched DNA structures such as a movable replication fork. This activity is strongly stimulated in the presence of CENPS and CENPX (PubMed:20347429). In complex with FAAP24, efficiently binds to single-strand DNA (ssDNA), splayed-arm DNA, and 3'-flap substrates (PubMed:17289582). In vitro, on its own, strongly binds ssDNA oligomers and weakly fsDNA, but does not bind to dsDNA (PubMed:16116434).

> Gene Ontology [ TOP ]
Biological Process	GO:0000712 resolution of meiotic recombination intermediates GO:0006260 DNA replication GO:0006261 DNA-dependent DNA replication GO:0006310 DNA recombination GO:0007059 chromosome segregation GO:0007126 meiotic nuclear division GO:0007127 meiosis I GO:0007131 reciprocal meiotic recombination GO:0031297 replication fork processing GO:0035825 reciprocal DNA recombination GO:0036297 interstrand cross-link repair GO:0045005 DNA-dependent DNA replication maintenance of fidelity GO:0045132 meiotic chromosome segregation GO:0051304 chromosome separation GO:0051307 meiotic chromosome separation GO:0051321 meiotic cell cycle GO:0090305 nucleic acid phosphodiester bond hydrolysis GO:0098813 nuclear chromosome segregation GO:1903046 meiotic cell cycle process
Molecular Function	GO:0003682 chromatin binding GO:0004386 helicase activity GO:0004518 nuclease activity
Cellular Component	GO:0043240 Fanconi anaemia nuclear complex GO:0071821 FANCM-MHF complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03460 Fanconi anemia pathway
Reactome	R-HSA-73894: DNA Repair R-HSA-6783310: Fanconi Anemia Pathway

Summary
Symbol	FANCM
Name	Fanconi anemia, complementation group M
Aliases	FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location	14q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FANCM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	FANCM
Name	Fanconi anemia, complementation group M
Aliases	FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location	14q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FANCM in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FANCM
Name	Fanconi anemia, complementation group M
Aliases	FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location	14q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FANCM in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.005	0.98
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.226	0.618
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.173	0.635
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.221	0.492
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.015	0.993
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.484	0.811
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.047	0.854
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.105	0.921
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.023	0.983
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.079	0.918
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.603	0.537
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.1	0.118

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FANCM in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	7.1	17.9	0.405
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	18.5	2.7	15.8	0.0147
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	18.5	3.4	15.1	0.0291
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FANCM
Name	Fanconi anemia, complementation group M
Aliases	FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location	14q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FANCM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FANCM
Name	Fanconi anemia, complementation group M
Aliases	FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location	14q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FANCM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FANCM. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FANCM
Name	Fanconi anemia, complementation group M
Aliases	FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location	14q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FANCM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FANCM
Name	Fanconi anemia, complementation group M
Aliases	FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location	14q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FANCM expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FANCM
Name	Fanconi anemia, complementation group M
Aliases	FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location	14q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FANCM and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FANCM
Name	Fanconi anemia, complementation group M
Aliases	FAAP250; KIAA1596; ATP-dependent RNA helicase FANCM; fanconi anemia-associated polypeptide of 250 kDa; prote ......
Chromosomal Location	14q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FANCM collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FANCM